phylomers structural diversity, page-3

Hi POS,

Have a read of page 15 from the Annual Report:

http://phylogica.com/media/articles/Investors---ASX-Announcements/20131031-Annual-Report-to-shareholders-1137/42khflc8x0k4t6.pdf

Also this link:

http://researchers.uq.edu.au/research-project/15615

And this:

Taken from the April 26, 2012 announcement - "Phylogica granted patent for Synthetic Phylomer Libraries":

There are numerous applications of the newly patented technology, including the rational design of Phylomer libraries in parallel formats on solid surfaces, such as peptide arrays or beads. Array formats enable tens of thousands of peptides to be screened against multiple targets on a single miniature ‘chip’, significantly reducing the time and cost of identifying relevant drug candidates. The technology is highly amenable to scaling using multiple chips to screen hundreds of thousands to millions of peptides at a time. The technology also enhances various value-added uses of the Company’s platform, including direct phenotypic screening of Phylomer libraries for the discovery of, for example, novel antivirals, antibiotics or anticancer agents. In addition, array formats facilitate the construction of a range of high-density Phylomer libraries, which can be used for new applications of the platform, such as the identification of disease biomarkers for the development of novel diagnostic products.

http://phylogica.com/media/articles/Investors---ASX-Announcements/20120426-Patent-Granted-for-Synthetic-Phylomer-Libraries-982/425ttnt9s3887t.pdf

What we know is that the cost to develop the chip will be low. Once they have constructed and validated the chip (which could take rough guess another 6-12 months??), the biosensor could potentially be on the market soon after. Another point that I wanted to highlight is that not only do Phylogica's Synthetic Phylomers have a role in the development of these Biosensors but it appears that the company's other technologies may also play a very important part in the construction and validation of the new Phylomer Chip. Huge advantage.

It may seem like a long wait, but they get this right and there will nothing on the market like it, due to the structural diversity of the peptide libraries. Well worth the wait in my opinion.

Hope this helps.

Tony